



Revolutionizing aortic care for life.

Investor Presentation – Supplemental Slides
May 18, 2017

New Product Pipeline*

	2017	2018	2019	2020	2021
Nellix®	AP	LA		US Gen2, Japan	China
Nellix® CHEVAS			EU	AP, LA	US
AFX®2	EU	Japan	LA		
Ovation iX™	AP	LA, Japan			
Ovation Alto™			EU, US	AP, LA, Japan	China



*Estimated regulatory approvals.

Safe Harbor

Forward-Looking Statements

This presentation includes statements that may be forward-looking statements. The words “estimate” and similar expressions, among others, generally identify forward-looking statements. Forward-looking statements used in this presentation include those with respect to regulatory approvals. Endologix cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, changes to laws and regulations applicable to our industry, progress of our ongoing clinical trials, clinical trial results, decisions and the timing of decisions of regulatory authorities regarding our potential future products. Additional information about the factors that may affect Endologix’s operations and results is set forth in Endologix’s annual and periodic reports filed with the Securities and Exchange Commission (the “SEC”). Endologix undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law